Dhanwel Hybrid Seeds Limited
Open now19–21 Aug 2026
Updated 2026-08-21 (IST)
Business overview
Our Company is engaged in the business of seed manufacturing, which includes the development, multiplication, processing, and supply of seeds for a variety of field crops and vegetables.
Profit & Loss
Rs crore · AnnualLatest year highlighted in green. Sparklines show the trend.
| 2023-24 | 2024-25 | 2025-26 | ||
|---|---|---|---|---|
| Sales | 35 | 44 | 75 | |
| Operating Profit | — | — | — | |
| OPM % | — | — | — | |
| Net Profit | — | — | — | |
| Total Debt | 2 | 6 | 8 |
Offer structure
Total: ₹0 cr. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders.
Use of proceeds- Funding towards Repayment or prepayment, in full or in part, of borrowings availed by our Company from banks and financial institutions — ₹8 cr
- Funding the working capital requirements of our Company — ₹12 cr
- General Corporate Purpose
Promoters
- Mr. Kishankumar Gordhanbhai Meghani — Chairman and Managing Director
- Mr. Vimal Mansukhbhai Vekariya — Whole-Time Director
- Mr. Sudhir Mohanbhai Pipaliya — Non-Executive Director
- Mr. Nikul Mansukhbhai Vekariya — Promoter
Strengths & risks
Company-stated strengths and disclosed risk factors from the offer document.
- Wide Range of Seeds and its Variants (p.144)
- Quality Assurance (p.144)
- Customer Satisfaction (p.144)
- Experienced Promoter supported by dedicated Management team (p.144)
- Order Book Visibility (p.145)
- Our business is subject to seasonality and climatic conditions, which could impact demand for our products and affect our financial performance. (p.30)
- Certain delays, discrepancies and Omissions have been detected in our statutory records, as well as in records related to the submission of returns to the concerned Registrar of Companies. (p.30)
- Major portion of our transactions are conducted in cash, which may expose us to operational, regulatory, and financial risks. (p.32)
- Certain delays in statutory filings under the Companies Act, 2013 may lead to financial and regulatory consequences for our Company. (p.32)
- Non-compliance with certain procedural requirements under Section 42 of the Companies Act, 2013 relating to a private placement of equity shares may expose our Company to regulatory action, penalties, and other adverse consequences. (p.33)
Peer comparison — DRHP median P/E 26.5x
Live BSE prices| Company | CMP | P/E | OPM% | ROE% | Source |
|---|---|---|---|---|---|
| Bombay Super Hybrid Seeds Limited | Rs 88.9 -1.1% | 39.1x | 9.7% | — | live |
| Upsurge Seeds of Agriculture Limited | — | 14.0x | — | — | DRHP |
P/E from offer document where live data unavailable. Not a fair-value judgement.
Market & competition
The seed market structure remains fragmented, with the top five firms capturing a good share of revenue, followed by dozens of regional seed houses. The company competes with multinationals like Bayer AG and Corteva Inc., and regional champions like Nuziveedu Seeds and Kaveri Seeds.
Future outlook
Our Company seeks to strengthen its presence in existing markets while gradually expanding its reach to additional geographies, based on market opportunities and demand conditions. We intend to continue efforts aimed at enhancing brand visibility and recognition in existing and potential markets under the brand name 'Dhanwel'. Additionally, we seek to improve operational efficiency across production and processing activities to manage costs effectively.
Never miss an IPO like this
Every upcoming IPO analysed — subscription, GMP and a DRHP breakdown — in your inbox, free. One email when each one opens.
Sources & method
Subscription and issue data come from the NSE and BSE exchange feeds, with the third-party aggregator, clearly labelled, where an exchange feed is unreachable. DRHP analysis is extracted from the offer document itself, every figure cited to its page. Each figure on the page carries its source and its timestamp.
Grey-market premium (GMP) is unregulated.
Every GMP figure is a self-reported grey-market estimate — no exchange, regulator or clearing body records or audits it, and there is no settlement guarantee or recourse. Shown for context only; never decide on GMP alone. New to GMP? The 30-second explainer →